Related Experiment Video

Updated: Oct 26, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

Lnc-STYK1-2 regulates bladder cancer cell proliferation, migration, and invasion by targeting miR-146b-5p expression

Ranran Dai1, Qingping Jiang2, You Zhou1

  • 1Guangdong Key Laboratory of Urology, Guangzhou Medical University, Guangzhou, China.

Cancer Cell International
|August 1, 2021
PubMed
Abstract

Insights

Long noncoding RNA (lncRNA) lnc-STYK1-2 suppresses bladder cancer progression. It inhibits cell proliferation, migration, and tumorigenesis by regulating miR-146b-5p and ITGA2 expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Noncoding RNAs play a role in cancer development.
  • The involvement of noncoding RNAs in bladder cancer is not well understood.
  • This study focuses on the long noncoding RNA (lncRNA) lnc-STYK1-2 in bladder cancer.

Purpose of the Study:

  • Investigate the role of lnc-STYK1-2 in bladder cancer tumorigenesis.
  • Determine the molecular mechanisms underlying lnc-STYK1-2's function.
  • Identify potential therapeutic targets for bladder cancer.

Main Methods:

  • RNA sequencing and quantitative PCR for lncRNA and mRNA profiling.
  • Cell proliferation, migration, and invasion assays (MTS, Transwell).
  • In vivo xenograft models, dual-luciferase reporter assays, and Western blotting.

Main Results:

  • lnc-STYK1-2 expression is decreased in bladder cancer tissues.
  • Silencing lnc-STYK1-2 promotes bladder cancer cell proliferation, migration, invasion, and tumorigenesis.
  • lnc-STYK1-2 targets miR-146b-5p, which in turn regulates ITGA2 expression and downstream signaling pathways (AKT/STAT3/NF-kB).

Conclusions:

  • lnc-STYK1-2 acts as a tumor suppressor in bladder cancer.
  • The lnc-STYK1-2/miR-146b-5p/ITGA2 axis is crucial for regulating bladder cancer cell behavior.
  • Targeting this pathway may offer a novel therapeutic strategy for bladder cancer.
Keywords:
AKT/STAT3/NF-kBBladder cancerITGA2Lnc-STYK1-2Migration and invasionProliferationmiR-146b-5p

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.4K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.0K